AstraZeneca Plc ( AZN ) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.

• AZN is approaching key resistance levels. Find out why here.

The company released topline data in October.

The trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average SBP compared with placebo at 12 weeks.

Efficacy was observed throughout the 24 hours, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.

Baxdrostat met the primary endpoint, delivering clinically meaningful and consistent blood pressure reductions in patients with treatment-resistant hypertension.

Also Read: AstraZeneca’s Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

At 12 weeks, the placebo-adjusted reduction in ambulatory 24-hour average SBP was 14.0 mmHg.

Baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial.

Baxdrostat demonstrated statistically significant and clinically meaningful reductions in key secondary endpoints, including ambulatory night-time average SBP and seated SBP, consistent with data from the BaxHTN trial.

Significantly more patients treated with baxdrostat (71%) achieved an ambulatory 24-hour average SBP of less than 130 mmHg compared with patients receiving placebo (17%).

Full results from the Bax24 trial were presented at the Emerging Opportunities for Managing Cardiometabolic Syndrome late breaker session at the American Heart Association (AHA) Scientific Sessions 2025.

AstraZeneca ( AZN ) acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023

AZN Price Action: AstraZeneca ( AZN ) stock is up 2.49% at $86.68 at publication on Monday.

Read Next:

Opendoor’s ‘Major Transformation Is Underway’ — With 2026 Breakeven In Sight, JPMorgan Says